Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk
Ημερομηνία
2016Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Background/purpose A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors alirocumab and evolocumab. We aimed to investigate the effect PCSK9 inhibition on stroke risk in a meta-analysis involving data from randomized studies with alirocumab and evolocumab. Methods Data from pre-specified combined analysis of 4465 patients who completed phase 2 or 3 studies of evolocumab over a period of 1 year and a randomized trial on alirocumab including 2341 patients with hyperlipidemia on maximally tolerated statin who were at high risk for coronary heart disease over a period of 1.5 years were used. Results The number of patients having an ischemic stroke was small in both trials. PCSK9 inhibition showed no significant effect on stroke rate (risk ratio 1.43; 95% CI, 0.45–4.57, p = 0.55). No significant differences in stroke risk were evident when transient ischemic attacks were included in the analysis (risk ratio 0.65; 95% CI, 0.25–1.68, p = 0.37). No hemorrhagic strokes were reported in either study. Conclusion Although a benefit towards reduction of cardiovascular events in the overall has been documented, longer exposure is warranted to be able to evaluate the effect on stroke risk. © 2016 European Federation of Internal Medicine.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Lipid-lowering treatment in peripheral artery disease
Katsiki N., Giannoukas A.D., Athyros V.G., Mikhailidis D.P. (2018)Peripheral artery disease (PAD) is characterized by increased cardiovascular (CV) risk, limb morbidity and all-cause mortality. According to the current guidelines (2016) of the American Heart Association/American College ... -
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
Achimastos A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., Chrysochoou C., Drogari E., Elisaf M., Ganotakis E., Goudevenos I., Ioannidis I., Kolovou G., Kotsis V., Lekakis I., Liberopoulos E., Melidonis A., Nikolaou V., Ntaios G., Papanas N., Pappas S., Pitsavos C., Rallidis L., Richter D., Skoumas I., Tentolouris N., Tousoulis D., Tselepis A., Tsioufis K., Tziakas D., Tziomalos K., Vardas P., Vlachopoulo C., Vlahakos D. (2016)Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the ... -
Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis
Sagris D., Ntaios G., Georgiopoulos G., Pateras K., Milionis H. (2021)[No abstract available]